Dropped drugs cast shadow over Merck KGaA 1Q growth
This article was originally published in Scrip
Executive Summary
Merck KGaA reported relatively healthy first-quarter earnings on 14 May, with moderate revenue and sales growth across the group and double-digit earnings per share growth.